Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Michael Moher a Department of Primary Health Care, University of
Oxford, Institute of Health Sciences, Oxford OX3 7LF, b MRC Clinical Trials Unit, 222 Euston Road, London NW1
2AD
Correspondence to: M Moher michael.moher{at}dphpc.ox.ac.uk
| |
Abstract |
|---|
|
|
|---|
Objective:
To assess the effectiveness of three
different methods of promoting secondary prevention of coronary heart
disease in primary care.
Design:
Pragmatic, unblinded, cluster randomised
controlled trial.
Setting:
Warwickshire.
Subjects:
21 general practices received intervention; outcome measured in 1906 patients aged 55-75 years with established coronary heart disease.
Interventions:
Audit of notes with summary feedback to
primary health care team (audit group); assistance with setting up a
disease register and systematic recall of patients to general
practitioner (GP recall group); assistance with setting up a disease
register and systematic recall of patients to a nurse led clinic (nurse recall group).
Main outcome measures:
At 18 months' follow up:
adequate assessment (defined) of 3 risk factors (blood pressure,
cholesterol, and smoking status); prescribing of hypotensive agents,
lipid lowering drugs, and antiplatelet drugs; blood pressure, serum
cholesterol level, and plasma cotinine levels.
Results:
Adequate assessment of all 3 risk factors was
much more common in the nurse and GP recall groups (85%, 76%) than
the audit group (52%). The advantage in the nurse recall compared with
the audit group was 33% (95% confidence interval 19% to 46%); in
the GP recall group compared with the audit group 23% (10% to 36%),
and in the nurse recall group compared with the GP recall group 9%
(
3% to 22%). However, these differences in assessment were not
reflected in clinical outcomes. Mean blood pressure (148/80, 147/81,
148/81 mm Hg), total cholesterol (5.4, 5.5, 5.5 mmol/l), and cotinine
levels (% probable smokers 17%, 16%, 19%) varied little between the
nurse recall, GP recall, and audit groups respectively, as did
prescribing of hypotensive and lipid lowering agents. Prescribing of
antiplatelet drugs was higher in the nurse recall group (85%) than the
GP recall or audit groups (80%, 74%). After adjustment for baseline
levels, the advantage in the nurse recall group compared with the audit
group was 10% (3% to 17%), in the nurse recall group compared with
the GP recall group 8% (1% to 15%) and in the GP recall group
compared with the audit group 2% (
6% to 10%).
Conclusions:
Setting up a register and recall system
improved patient assessment at 18 months' follow up but was not
consistently better than audit alone in improving treatment or risk
factor levels. Understanding the reasons for this is the key next step in improving the quality of care of patients with coronary heart disease.
|
What is already known on this topic
What this study adds
|
| |
Introduction |
|---|
|
|
|---|
Patients with established coronary heart disease are at serious risk of subsequent vascular events (non-fatal myocardial infarction, non-fatal strokes, and vascular deaths).1 This risk can be reduced by effective clinical and preventive care.2 Evidence also exists that the quality of such care in hospitals and general practices is inadequate. Assessment of risk is often incomplete, and many patients whose risk could be reduced are not receiving optimal treatment. 3 4
Last year the national service framework for coronary heart disease set as a target in England that general practitioners and primary care teams should aim to identify all people with established cardiovascular disease and offer them comprehensive advice and appropriate treatment to reduce their risks.5 This will require important changes in clinical practice and in the systems of care. Methods of achieving quality improvement and change in clinical practice vary in their effectiveness, and these have recently been reviewed.6 Audit and feedback, the provision of guidelines (and facilitation to assist their adoption), record systems, improved communications between primary and secondary care, patient reminders, and nurse led clinics in general practice have all been advocated and tested as methods of producing change in practice for patients with established coronary heart disease.7-12 They have not been compared directly and have different potential costs.
We aimed to compare the effectiveness of three different interventions
for improving the secondary preventive care of patients with coronary
heart disease delivered at the level of general practice: audit and
feedback; recall to a general practitioner; and recall to a nurse
clinic. The intervention was assessed in a pragmatic, unblinded,
cluster randomised controlled trial that attempted to include all
general practices in Warwickshire.
| |
Participants and methods |
|---|
|
|
|---|
Recruitment of practices
In June 1997 we invited all 79 general practices in
Warwickshire to participate in the study and eventually recruited 21 practices. The practices that had expressed no interest in the study
were smaller, less likely to employ practice nurses, and less likely to
be involved in training than others.
Identification of patients
All paper and computer records of patients aged 55-75 years were hand searched by six external auditors, and patients with
established coronary heart disease were identified.13 Coronary heart disease was defined as a previous diagnosis of myocardial infarction, stable angina, or revascularisation by percutaneous transluminal coronary angioplasty or coronary artery bypass. Patients who had single episodes of chest pain diagnosed as
possible angina but who did not continue to take any antianginal drugs
were not included. In all, 2142 patients were identified as having
coronary heart disease.
Interventions
Audit and feedback (audit
group)
Practices were given summary audit results at a practice
meeting (one practice requested written material only). The results
presented were the number of patients with myocardial infarction,
angina, and revascularisation; the prevalence of identified coronary
heart disease in the practice; and the proportions of patients with
"adequate assessment" (see "Study outcomes" for definition) and
treatment with antiplatelet drugs, hypotensive agents, and lipid
lowering drugs. Anonymised data from other practices in the study were
given for comparison. Practices were asked to provide usual care and
were given no further support during the trial.
Practices
were given the same patient information as was given to the audit group
but were also given the names of patients identified as having coronary
heart disease. MM discussed and agreed guidelines for secondary
prevention with the practice doctors and gave ongoing support in
setting up a register and recall system for regular review of patients
with coronary heart disease by their general practitioner.
Recall to nurse clinic (nurse recall group)
Practices were
given the same patient information as was given to the GP recall group.
The trial's nurse facilitator (LW) gave ongoing support to the
practices in setting up a register and recall system for systematic
review of patients with coronary heart disease in a nurse led clinic.
After discussion and agreement of guidelines for secondary prevention,
the practice doctors and nurses agreed the clinic protocol, and the
nurses received education to implement it.
Study outcomes
The primary outcome was adequate assessment at 18 months' follow up. At the first audit adequate assessment was defined
as (a) a record of blood pressure since diagnosis and, if
on any occasion this was recorded as exceeding 140 mm Hg systolic or
90 mm Hg diastolic, a record of a follow up blood pressure in the
previous two years; (b) a record of serum cholesterol measurement since diagnosis and, if any reading was
5.5 mmol/l, a
record of repeat cholesterol measurement in the previous two years;
(c) a record of smoking habit and, for smokers, a record of
review in the previous two years. At the second audit the same criteria
were applied, except that a blood pressure reading in the previous two
years was mandatory. The main secondary outcomes were recorded
treatment with hypotensive agents, lipid lowering drugs, and
antiplatelet drugs.
|
20 ng/ml was
taken to indicate non-smoking.14
| |
Results |
|---|
|
|
|---|
Adequate assessment
At baseline about 30% of patients were adequately assessed overall; this proportion rose markedly during the trial in all
three groups (table 2). The greatest contribution to the overall rise
came from the improvement in assessing cholesterol levels, but
assessment of smoking status and blood pressure also increased,
especially in the GP recall and nurse recall
groups.
|
3% to 22%)) was not significant. The three components of adequate
assessment all followed a similar pattern.
Drug treatment
The much higher levels of adequate assessment at follow up
in the GP and nurse recall groups were not matched by similar
differences in drug treatment (table 3). Prescribing of hypotensive
drugs showed minimal change in all three groups, but over two thirds
(68%; 1290/1906) of patients were already being treated with
hypotensive drugs at baseline. Among the 1782 patients adequately
assessed for blood pressure at follow up, raised blood pressure (>160
mm Hg systolic or >100 mm Hg diastolic at the most recent measurement)
was observed in 18% (84/478) of patients in the audit group, 17%
(113/663) in the GP recall group, and 13% (86/641) in the nurse recall
group. Of the 283 patients in all groups with this higher blood
pressure, 55 (19%) were not being treated with hypotensive
drugs.
|
Clinical examination
Of the 1824 patients invited for assessment, 74% (1342)
attended. Attendance rates for each group were similar. Table 4
shows that mean blood pressure, serum cholesterol (total and high
density lipoprotein) level, and smoking status did not differ
significantly between the three groups.
|
| |
Discussion |
|---|
|
|
|---|
We already know from studies of other chronic conditions
that high quality care needs to be systematic and that outcome tends to
be better when quality assurance is introduced on the basis of
registration and planned follow up.
15 16
This trial shows that the simple expedient of setting up a patient register for a
general practice markedly increases the probability of planned follow
up taking place. It also shows that this benefit can be achieved
whether responsibility for follow up lies with the general practitioner
or with the practice nurse, and indeed follow up by nurses seems to be
more effective. The only significant treatment benefit we observed was
an improvement in the prescribing of antiplatelet drugs in the nurse
recall group, although in the absence of complete information on self
medication we cannot be sure that this reflects a genuine increase in
use of such drugs. As increasing demands are being made on primary care
to deliver systematic care for patients with chronic disease
without
the prospect of a similar increase in the number of general
practitioners
this is an important finding.
The trial also showed a lack of difference between the GP and nurse recall groups in clinical outcome. This is entirely consistent with previous trials of secondary prevention of coronary heart disease in general practice that have reported objective measurements of patient risk factors. 8 10
Lack of clinical benefit
Why are we managing consistently to improve the process of
care without achieving any apparent clinical benefit? We suggest
several hypotheses, some of which were advanced by the medical and
nursing staff in participating practices in informal interviews and
discussions after the trial had ended.
Conclusions
The lessons to be learned from this trial are threefold:
helping practices to set up a practice register of eligible patients
increases follow up and adequate assessment; care by nurses is as
effective as, and possibly more effective than, systematic care by
doctors; and adequate assessment does not necessarily translate into
better care or clinical outcome. Understanding why this is, and what we
should do about it, is the key next step in improving the quality of
care of patients with established coronary heart disease.
| |
Acknowledgments |
|---|
The ASSIST Trial Collaborative Group also includes G Fowler, E Fullard, K Johnston, A Gray, M Murphy, A Neil, S Thompson, F Wells, Wiles R, and L Youngman.
Contributors: MM contributed to the study protocol and was medical coordinator of the trial. PY contributed to the study protocol, gave ongoing research leadership, and was responsible for the statistical analysis. LW designed and implemented the nurse led intervention and was nursing coordinator of the trial. RT made an important contribution to the statistical analysis and interpretation. TS initiated and was responsible for the study protocol. DM discussed core ideas and gave intellectual stimulus. MM, PY, TS, and DM drafted the text of the paper with the support of the other authors. TS is guarantor for the study.
| |
Footnotes |
|---|
Funding: The study was funded by a national research and development programme grant from the NHS Executive. MM received a training fellowship jointly from the Medical Insurance Agency and the Royal College of General Practitioners.
Competing interests: LW has been reimbursed by Pfizer, the manufacturer of atorvastatin, for attending a conference.
The full version of this paper
appears on the BMJ's website
| |
References |
|---|
|
|
|---|
| 1. |
Shaper AG, Pocock SJ, Walker M, Phillips AN, Whitehead TP, Macfarlane PW.
Risk factors for ischaemic heart disease: the prospective phase of the British regional heart study.
J Epidemiol Community Health
1985;
39:
197-209 |
| 2. |
Moher M.
Evidence of effectiveness of interventions for the secondary prevention and treatment of coronary heart disease in primary care a review of the literature.
Oxford: NHS Executive, Anglia and Oxford Regional Health Authority, 1995.
|
| 3. |
ASPIRE Steering Group.
A British Cardiac Society survey of the potential for the secondary prevention of coronary heart disease: ASPIRE (action on secondary prevention through intervention to reduce events) principal results.
Heart
1996;
75:
334-342 |
| 4. |
Campbell NC, Thain J, Deans HG, Ritchie LD, Rawles JM.
Secondary prevention in coronary heart disease: a baseline survey of provision and possibility in general practice.
BMJ
1998;
316:
1430-1434 |
| 5. | Department of Health. A national service framework for coronary heart disease. London: DoH, 2000. |
| 6. | Getting evidence into practice. Effective Health Care 1999;5(1). |
| 7. |
Campbell N, Thain J, Deans H, Ritchie L, Rawles J, Squair J.
Secondary prevention clinics for coronary heart disease: randomised trial of effect on health.
BMJ
1998;
316:
1434-1437 |
| 8. |
Cupples M, McKnight A.
Randomised controlled trial of health promotion in general practice for patients at high cardiovascular risk.
BMJ
1994;
309:
993-996 |
| 9. |
Feder G, Griffiths C, Eldridge S, Spence M.
Effect of postal prompts to patients and general practitioners on the quality of primary care after a coronary event (POST): randomised controlled trial.
BMJ
1999;
318:
1522-1526 |
| 10. |
Jolly K, Bradley F, Sharp S, Smith H, Thompson S, Kinmonth AL, et al.
Randomised controlled trial of follow up care in general practice of patients with myocardial infarction and angina: final results of the Southampton heart integrated care project (SHIP).
BMJ
1999;
318:
706-711 |
| 11. |
McCartney P, Macdowall W, Thorogood M.
A randomised controlled trial of feedback to general practitioners of their prophylactic aspirin prescribing.
BMJ
1997;
315:
35-36 |
| 12. |
Soumerai SB, Avorn J.
Principles of educational outreach ("academic detailing") to improve clinical decision making.
JAMA
1990;
263:
549-556 |
| 13. |
Moher M, Yudkin P, Turner R, Schofield T, Mant D, for the ASSIST (Assessment of Implementation Strategies) Trial Collaborative Group.
An assessment of morbidity registers for coronary heart disease in primary care.
Br J Gen Pract
2000;
50:
706-709 |
| 14. |
Jarvis MJ, Tunstall-Pedoe H, Feyerabend C, Vesey C, Saloojee Y.
Comparison of tests used to distinguish smokers from nonsmokers.
Am J Public Health
1987;
77:
1435-1438 |
| 15. |
Feder G, Griffiths C, Highton C, Eldridge S, Spence M, Southgate L.
Do clinical guidelines introduced with practice based education improve care of asthmatic and diabetic patients? A randomised controlled trial in general practices in east London.
BMJ
1995;
311:
1473-1478 |
| 16. |
Pierce M, Lundy S, Palanisamy A, Winning S, King J.
Prospective randomised controlled trial of methods of call and recall for cervical cytology screening.
BMJ
1989;
299:
160-162 |
(Accepted 15 March 2001)
Read all Rapid Responses